StreetAlpha.app
Home › Stocks › BLTE

Belite Bio, Inc (BLTE)

Healthcare
$127.38
▼ −15.65%
LAST CLOSE · NOV 20

Belite Bio is a San Diego drug developer working on oral treatments for degenerative retinal diseases that cause vision loss. It last closed at $127.38 on Nov 20, down 15.65% on the day. Over the last 12 months BLTE insiders bought $0 of stock on the open market and sold $41.0M, according to SEC Form 4 filings.

AI Auto Pilots
Is BLTE in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold BLTE.

Key Stats

Fiscal 2025
Results
Net income
−$77.6M
Free cash flow
−$37.1M
Balance sheet
Cash & equivalents
$352.9M
At Dec 31
Shareholder equity
$770.5M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$9.7M−$9.7MFY2021FY2022: −$12.6M−$12.6MFY2022FY2023: −$31.6M−$31.6MFY2023FY2024: −$36.1M−$36.1MFY2024FY2025: −$77.6M−$77.6MFY2025

From BLTE's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Mar 31). Per share figures are left out because the US listing can represent a different number of shares.

Next report
—
No date on the calendar yet
Consensus EPS forecast
EPS and revenue estimates
Year-ago EPS
Same quarter last year
Options-implied move
Move priced in by options
Analyst consensus
Ratings from the last 90 days
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Analyst calls from around the web
Last 90 days on BLTE: 0 upgrades, 0 downgrades, 0 initiations
Canaccord Genuity GroupTarget raised
Nov 16  

StreetAlpha's curated list of analyst calls collected from around the web. It may be incomplete or inaccurate, is not a consensus and is not advice.

AI Starter and AI Pro
Full analyst coverage on BLTE
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on BLTE

Technical Analysis

BLTE · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 20% below its 20 day and 24% below its 50 day average. It is 25% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 32), near oversold. The nearest support is the Pivot S1 at $119.90, and the nearest resistance the Pivot at $127.48.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 7.3%/day
Key levels
$200.0052 week high+57.0%
$159.43200 day average+25.2%
$159.17100 day average+25.0%
$157.6150 day average+23.7%
$152.9720 day average+20.1%
$151.41Swing high (May 29)+18.9%
$134.96Pivot R1+6.0%
$127.48Pivot+0.1%
$127.38Last close
$119.90Pivot S1−5.9%
$105.8852 week low−16.9%
Indicators
RSI (14)31.58Weak, oversold below 30Neutral
MACD-1.80Below its signal lineBearish
Stochastic33.0Middle of its rangeNeutral
ADX (14)19.0No clear trend
Williams %R-85.5Oversold below −80, overbought above −20Oversold
CCI (20)-288.5Oversold below −100, overbought above 100Oversold
Rate of change−17.4%Change over 10 sessionsBearish
ATR (14)$9.34Typical daily range, 7.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for BLTE

What happened before

See how BLTE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow BLTE usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How BLTE has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2022.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for BLTEHow many large options trades hit BLTE, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

BLTE Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲57 buying vs 42 selling
  • ●Held by funds -0.1 pts
  • ▲Funds holding +15
  • ▼Superinvestors: 0 added, 4 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding9681+18.5%
In funds' top 10550.0%
Held by funds23.9%24.1%−0.1 pts
New / increased28 / 2922 / 28+14.0%
Reduced / sold out30 / 1222 / 17+7.7%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See BLTE institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

BLTE Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$41.0M28 sales · 5 insiders
93% of the selling was under pre-arranged trading plans.
2026-04 sold $4.9M2026-05 sold $723K2026-06 sold $2.9M2026-08 sold $132K2026-09 sold $31.9M2026-10 sold $83K2026-11 sold $332KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 12Hendrik Peter SchollChief Medical OfficerSale plan2,000$165.99$332K
Oct 1Hendrik Peter SchollChief Medical OfficerSale plan500$165.32$83K
Sep 8Hao-Yuan ChuangCFOSale plan67,395$189.98$12.8M
Sep 8Yu-Hsin LinCEOSale plan100,435$190.00$19.1M
Aug 12Yu-Hsin LinCEOSale plan365$180.35$66K
Aug 12Hao-Yuan ChuangCFOSale plan367$180.35$66K
Every insider buy and sale for BLTE over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See BLTE insider trades →

From SEC Form 4 filings by BLTE's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BLTE is in one of them and how their past BLTE trades turned out.

BLTE in the AI portfolios
Loading…

BLTE News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered BLTE in an article yet. Here's the latest on the wider market.

BLTE in the news

About Belite Bio

Belite Bio is a drug development company based in San Diego, California. It is developing tinlarebant, a tablet taken once a day, for people with degenerative retinal diseases that cause progressive vision loss, including geographic atrophy and Stargardt disease type 1. The company also has an earlier stage oral compound aimed at metabolic conditions such as fatty liver disease and type 2 diabetes. Its intended users are patients with these eye conditions and the doctors who would treat them if a product is approved.

Headquarters
San Diego, CA